Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.50 |
| ▸ | CDK2 | P24941 | 20/20 | 0.50 |
| ▸ | CCND1 | P24385 | 19/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 19/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098023 | 1.00 | CCNE1 (0.50) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27089924 | 0.88 | CCNE1 (0.64) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL30517130 | 0.88 | CCNE1 (0.64) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL29640946 | 0.88 | CCNE1 (0.64) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL19857314 | 0.88 | CCNE1 (0.64) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL24572618 | 0.88 | CCNE1 (0.64) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL26095811 | 0.82 | CCNE1 (0.52) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL29640940 | 0.81 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL19857389 | 0.81 | CCND1 (0.60) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL25123234 | 0.81 | CCNE1 (0.44) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4110782-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | Fochon Biosciences, Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |